NO993540L - Ny formulering for inhalering som har bulkdensitet ved helling fra 0,28 til 0,38 g/ml, omfattende tebutalinsulfat,en fremgangsmÕte for fremstilling av formuleringen og anvendelse derav - Google Patents

Ny formulering for inhalering som har bulkdensitet ved helling fra 0,28 til 0,38 g/ml, omfattende tebutalinsulfat,en fremgangsmÕte for fremstilling av formuleringen og anvendelse derav

Info

Publication number
NO993540L
NO993540L NO993540A NO993540A NO993540L NO 993540 L NO993540 L NO 993540L NO 993540 A NO993540 A NO 993540A NO 993540 A NO993540 A NO 993540A NO 993540 L NO993540 L NO 993540L
Authority
NO
Norway
Prior art keywords
formulation
bulk density
tebutaline
inhalation
slope
Prior art date
Application number
NO993540A
Other languages
English (en)
Norwegian (no)
Other versions
NO993540D0 (no
Inventor
Jan Trofast
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO993540D0 publication Critical patent/NO993540D0/no
Publication of NO993540L publication Critical patent/NO993540L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
NO993540A 1997-01-20 1999-07-19 Ny formulering for inhalering som har bulkdensitet ved helling fra 0,28 til 0,38 g/ml, omfattende tebutalinsulfat,en fremgangsmÕte for fremstilling av formuleringen og anvendelse derav NO993540L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9700136A SE9700136D0 (sv) 1997-01-20 1997-01-20 New formulation
PCT/SE1998/000041 WO1998031353A1 (en) 1997-01-20 1998-01-13 New formulation for inhalation having a poured bulk density of from 0.28 to 0.38 g/ml, comprising terbutaline sulphate, a process for preparing the formulation and the use thereof

Publications (2)

Publication Number Publication Date
NO993540D0 NO993540D0 (no) 1999-07-19
NO993540L true NO993540L (no) 1999-09-20

Family

ID=20405456

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993540A NO993540L (no) 1997-01-20 1999-07-19 Ny formulering for inhalering som har bulkdensitet ved helling fra 0,28 til 0,38 g/ml, omfattende tebutalinsulfat,en fremgangsmÕte for fremstilling av formuleringen og anvendelse derav

Country Status (30)

Country Link
EP (1) EP1014955B1 (pl)
JP (1) JP2001509812A (pl)
KR (1) KR100528415B1 (pl)
CN (1) CN1195507C (pl)
AT (1) ATE263552T1 (pl)
AU (1) AU728768B2 (pl)
BE (1) BE1012009A5 (pl)
BR (1) BR9806893A (pl)
CA (1) CA2277891C (pl)
CZ (1) CZ295665B6 (pl)
DE (1) DE69823045T2 (pl)
EE (1) EE03950B1 (pl)
ES (2) ES2217535T3 (pl)
FR (1) FR2759905B1 (pl)
GR (1) GR980100023A (pl)
HU (1) HUP0000755A3 (pl)
ID (1) ID21929A (pl)
IE (1) IE980026A1 (pl)
IL (1) IL130839A (pl)
IS (1) IS2072B (pl)
NL (1) NL1008020C2 (pl)
NO (1) NO993540L (pl)
NZ (1) NZ336595A (pl)
PL (1) PL189551B1 (pl)
RU (1) RU2180562C2 (pl)
SE (1) SE9700136D0 (pl)
SK (1) SK283943B6 (pl)
TR (1) TR199901689T2 (pl)
UA (1) UA57765C2 (pl)
WO (1) WO1998031353A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
SE0200657D0 (sv) * 2002-03-04 2002-03-04 Astrazeneca Ab Novel Formulation
US8273331B2 (en) 2002-08-21 2012-09-25 Norton Healthcare Ltd. Inhalation compositions
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
DE102007049931A1 (de) 2007-10-18 2009-04-23 Pharmatech Gmbh Vorrichtung und Verfahren zur kontinuierlichen Herstellung von sphärischen Pulveragglomeraten
EP2255807A1 (en) 2009-05-26 2010-12-01 Sanofi-Aventis Method of treating sleep disorders using the combination of eplivanserin and zolpidem
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE17441T1 (de) * 1981-07-24 1986-02-15 Fisons Plc Inhalierbare arzneimittel, verfahren zu deren herstellung und pharmazeutische formulierungen diese enthaltend.
DE3268533D1 (en) * 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
RU2170082C2 (ru) * 1993-10-01 2001-07-10 Астра Актиеболаг Способ обработки лекарственного средства, устройство для формирования лекарственного средства и лекарственное средство
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination

Also Published As

Publication number Publication date
CA2277891A1 (en) 1998-07-23
EE03950B1 (et) 2003-02-17
CZ295665B6 (cs) 2005-09-14
KR20000070189A (ko) 2000-11-25
HUP0000755A3 (en) 2001-03-28
IE980026A1 (en) 1998-10-07
ID21929A (id) 1999-08-12
IS2072B (is) 2005-12-15
ES2149083B1 (es) 2001-05-16
PL189551B1 (pl) 2005-08-31
FR2759905A1 (fr) 1998-08-28
AU728768B2 (en) 2001-01-18
NL1008020A1 (nl) 1998-07-22
AU5786098A (en) 1998-08-07
UA57765C2 (uk) 2003-07-15
IL130839A0 (en) 2001-01-28
SK283943B6 (sk) 2004-05-04
EE9900293A (et) 2000-02-15
KR100528415B1 (ko) 2005-11-15
JP2001509812A (ja) 2001-07-24
NO993540D0 (no) 1999-07-19
WO1998031353A1 (en) 1998-07-23
CZ255899A3 (cs) 1999-10-13
CA2277891C (en) 2006-08-29
NZ336595A (en) 2001-01-26
ES2217535T3 (es) 2004-11-01
BE1012009A5 (fr) 2000-04-04
EP1014955B1 (en) 2004-04-07
SK96099A3 (en) 2000-01-18
NL1008020C2 (nl) 2000-01-18
EP1014955A1 (en) 2000-07-05
SE9700136D0 (sv) 1997-01-20
PL334526A1 (en) 2000-02-28
TR199901689T2 (xx) 1999-09-21
BR9806893A (pt) 2000-05-16
DE69823045T2 (de) 2004-10-21
CN1195507C (zh) 2005-04-06
FR2759905B1 (fr) 2001-03-09
CN1244120A (zh) 2000-02-09
HUP0000755A2 (hu) 2000-10-28
RU2180562C2 (ru) 2002-03-20
DE69823045D1 (de) 2004-05-13
IL130839A (en) 2004-12-15
ATE263552T1 (de) 2004-04-15
IS5107A (is) 1999-07-06
ES2149083A1 (es) 2000-10-16
GR980100023A (el) 1998-09-30

Similar Documents

Publication Publication Date Title
MY132999A (en) New formulation for inhalation
NO993537D0 (no) Ny formulering for inhalering som har en bulkdensitet ved helling fra 0,28 til 0,38 g/ml, omfattende budesonid
NO993538D0 (no) Ny formulering for inhalering som har en bulkdensitet ved helling fra 0,28 til 0,38 g/ml, omfattende formoterol
NO993540L (no) Ny formulering for inhalering som har bulkdensitet ved helling fra 0,28 til 0,38 g/ml, omfattende tebutalinsulfat,en fremgangsmÕte for fremstilling av formuleringen og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application